[go: up one dir, main page]

WO2012094679A3 - Compositions and methods for delivery of high-affinity oxygen binding agents to tumors - Google Patents

Compositions and methods for delivery of high-affinity oxygen binding agents to tumors Download PDF

Info

Publication number
WO2012094679A3
WO2012094679A3 PCT/US2012/020680 US2012020680W WO2012094679A3 WO 2012094679 A3 WO2012094679 A3 WO 2012094679A3 US 2012020680 W US2012020680 W US 2012020680W WO 2012094679 A3 WO2012094679 A3 WO 2012094679A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxygen
hemoglobin
increasing
tumor
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/020680
Other languages
French (fr)
Other versions
WO2012094679A2 (en
Inventor
P. Peter Ghoroghchian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vindico Nanobiotechnology LLC
Original Assignee
Vindico Nanobiotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES12732165T priority Critical patent/ES2718308T3/en
Priority to EP12732165.1A priority patent/EP2661275B1/en
Priority to US13/508,271 priority patent/US20130177641A1/en
Priority to DK12732165.1T priority patent/DK2661275T3/en
Application filed by Vindico Nanobiotechnology Inc filed Critical Vindico Nanobiotechnology Inc
Publication of WO2012094679A2 publication Critical patent/WO2012094679A2/en
Publication of WO2012094679A3 publication Critical patent/WO2012094679A3/en
Anticipated expiration legal-status Critical
Priority to US14/261,540 priority patent/US20140255477A1/en
Priority to US14/455,082 priority patent/US20140363496A1/en
Priority to US15/502,745 priority patent/US20170361126A1/en
Priority to US16/252,127 priority patent/US20200001110A1/en
Priority to US16/925,958 priority patent/US20200338361A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

While tumor hypoxia is recognized as a key barrier to effective chemo and radiation therapy of solid tumor malignancies, and an important biological mediator of more aggressive tumor phenotype and behavior for over 50 years, prior attempts to improve tumor oxygenation have relied on increasing the total amount of oxygen bound to each molecule of natural hemoglobin (e.g. through hyperbaric oxygen treatments), increasing the ease of release of oxygen from hemoglobin (through the introduction of exogenous allosteric small molecules), or increasing the total amount of oxygen in the body by injecting perfluorocarbon emulsions, or polymerized or pegylated compositions of natural human or bovine hemoglobin. The embodiments provide a novel approach of introducing into the vascular system agents that possess inherently higher-affinities for molecular oxygen that that of natural human hemoglobin, and coupling these agents with inert carriers that shield them from unwanted biological interactions within the body.
PCT/US2012/020680 2011-01-07 2012-01-09 Compositions and methods for delivery of high-affinity oxygen binding agents to tumors Ceased WO2012094679A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES12732165T ES2718308T3 (en) 2011-01-07 2012-01-09 Compositions and methods for administration to tumors of high oxygen affinity binding agents
EP12732165.1A EP2661275B1 (en) 2011-01-07 2012-01-09 Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
US13/508,271 US20130177641A1 (en) 2011-01-07 2012-01-09 Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
DK12732165.1T DK2661275T3 (en) 2011-01-07 2012-01-09 COMPOSITIONS AND METHODS FOR ADMINISTRATING THE HIGH OXYGEN EFFICIENCY TO TUMORS FOR THE ADMINISTRATION
US14/261,540 US20140255477A1 (en) 2011-01-07 2014-04-25 Compositions and Methods for Delivery of High-Affinity Oxygen Binding Agents to Tumors
US14/455,082 US20140363496A1 (en) 2011-01-07 2014-08-08 Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
US15/502,745 US20170361126A1 (en) 2011-01-07 2015-08-06 Compositions and Methods for Inducing Nanoparticle Mediated Microvascular Embolization of Tumors
US16/252,127 US20200001110A1 (en) 2011-01-07 2019-01-18 Compositions and methods for inducing nanoparticle-mediated microvascular embolization for tumors
US16/925,958 US20200338361A1 (en) 2011-01-07 2020-07-10 Compositions and methods for inducing nanoparticle-mediated microvascular embolization for tumors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161430628P 2011-01-07 2011-01-07
US61/430,628 2011-01-07
US201161435886P 2011-01-25 2011-01-25
US61/435,886 2011-01-25

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/508,271 A-371-Of-International US20130177641A1 (en) 2011-01-07 2012-01-09 Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
US14/261,540 Division US20140255477A1 (en) 2011-01-07 2014-04-25 Compositions and Methods for Delivery of High-Affinity Oxygen Binding Agents to Tumors
US14/455,082 Continuation-In-Part US20140363496A1 (en) 2011-01-07 2014-08-08 Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors

Publications (2)

Publication Number Publication Date
WO2012094679A2 WO2012094679A2 (en) 2012-07-12
WO2012094679A3 true WO2012094679A3 (en) 2012-10-26

Family

ID=46458007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/020680 Ceased WO2012094679A2 (en) 2011-01-07 2012-01-09 Compositions and methods for delivery of high-affinity oxygen binding agents to tumors

Country Status (6)

Country Link
US (2) US20130177641A1 (en)
EP (1) EP2661275B1 (en)
DK (1) DK2661275T3 (en)
ES (1) ES2718308T3 (en)
PT (1) PT2661275T (en)
WO (1) WO2012094679A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2941440B1 (en) 2013-01-07 2021-05-05 Omniox, Inc. Polymeric forms of h-nox proteins
FR3002146B1 (en) * 2013-02-15 2016-03-04 Hemarina USE OF ANNILIDES HEMOGLOBIN FOR THE TREATMENT OF CANCERS
EP2968374A4 (en) 2013-03-15 2016-08-10 Alphabet 3 Llc M Methods and compositions for enhancing oxygen levels in tissues
JP6764864B2 (en) * 2014-08-08 2020-10-07 ポセイダ セラピューティクス， インコーポレイテッド Compositions and Methods for Inducing Nanoparticle-Mediated Microvascular Embolus Formation in Tumors
WO2016090111A1 (en) * 2014-12-05 2016-06-09 Vindico NanoBio Technology Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
MX2017011847A (en) 2015-03-17 2018-06-06 Omniox Inc MODULATION OF TUMOR IMMUNITY BY O2 RELEASE PROTEIN.
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
WO2017039435A1 (en) 2015-08-28 2017-03-09 Rijksuniversiteit Groningen Means and methods for sustained oxygen release in situ
US9855445B2 (en) 2016-04-01 2018-01-02 Varian Medical Systems, Inc. Radiation therapy systems and methods for delivering doses to a target volume
US11213594B2 (en) 2016-04-29 2022-01-04 Poseida Therapeutics, Inc. Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
CN109803685B (en) 2016-08-16 2023-02-17 瑞士苏黎世联邦理工学院 Transmembrane pH-gradient polymersome and preparation method thereof
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
KR102588469B1 (en) 2016-09-30 2023-10-11 포세이다 테라퓨틱스, 인크. Modified stem cell memory t cells, methods of making and methods of using same
AU2017339511B2 (en) 2016-10-06 2021-12-02 Poseida Therapeutics, Inc. Inducible caspases and methods for use
US10183179B1 (en) 2017-07-21 2019-01-22 Varian Medical Systems, Inc. Triggered treatment systems and methods
US10549117B2 (en) 2017-07-21 2020-02-04 Varian Medical Systems, Inc Geometric aspects of radiation therapy planning and treatment
US11590364B2 (en) 2017-07-21 2023-02-28 Varian Medical Systems International Ag Material inserts for radiation therapy
US10843011B2 (en) 2017-07-21 2020-11-24 Varian Medical Systems, Inc. Particle beam gun control systems and methods
US10092774B1 (en) 2017-07-21 2018-10-09 Varian Medical Systems International, AG Dose aspects of radiation therapy planning and treatment
US11712579B2 (en) 2017-07-21 2023-08-01 Varian Medical Systems, Inc. Range compensators for radiation therapy
PT3668927T (en) 2017-09-12 2024-04-05 Eth Zuerich Transmembrane ph-gradient polymersomes for the quantification of ammonia in body fluids
US20200261495A1 (en) * 2017-09-24 2020-08-20 Aodh Lifesciences Private Limited Liquid oxygen encapsulation and methods to administer intravascular liquid oxygen
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
CN111556776B (en) 2017-11-16 2022-09-02 瓦里安医疗系统公司 Increased beam output and dynamic field shaping for radiation therapy systems
CN111712468A (en) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 Polymeric fluorophores, compositions containing the same, and methods of making and using the same
US10814144B2 (en) 2019-03-06 2020-10-27 Varian Medical Systems, Inc. Radiation treatment based on dose rate
US11116995B2 (en) 2019-03-06 2021-09-14 Varian Medical Systems, Inc. Radiation treatment planning based on dose rate
US10918886B2 (en) 2019-06-10 2021-02-16 Varian Medical Systems, Inc. Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping
WO2021013131A1 (en) * 2019-07-19 2021-01-28 Cheer Global Limited Hemoglobin-based therapeutic agents
US12390662B2 (en) 2020-04-02 2025-08-19 Siemens Healthineers International Ag System and method for proton therapy treatment planning with proton energy and spot optimization
US11865361B2 (en) 2020-04-03 2024-01-09 Varian Medical Systems, Inc. System and method for scanning pattern optimization for flash therapy treatment planning
US11541252B2 (en) 2020-06-23 2023-01-03 Varian Medical Systems, Inc. Defining dose rate for pencil beam scanning
US11957934B2 (en) 2020-07-01 2024-04-16 Siemens Healthineers International Ag Methods and systems using modeling of crystalline materials for spot placement for radiation therapy
US12064645B2 (en) 2020-07-02 2024-08-20 Siemens Healthineers International Ag Methods and systems used for planning radiation treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833974A (en) * 1996-04-17 1998-11-10 Teicher; Beverly A. Method of enhancing the effective life of oxygen-delivery agents
US20050129747A1 (en) * 2002-03-20 2005-06-16 Wolfgang Barnikol Use of one or more natural or modified oxygen carriers, devoid of plasma and cellular membrane constiuents, for externally treating open, in particular chronic wounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031741A1 (en) * 2000-06-29 2002-01-17 Sanguibio Tech Ag Externally applied oxygen carrier preparation for treating oxygen deficiency states of the skin, comprises active agent, specifically hemoglobin or its mixture with myoglobin, incorporated in a gel carrier
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
US8420118B2 (en) * 2009-09-10 2013-04-16 The Board Of Regents Of The University Of Oklahoma Anionic lipids and lipid nano-structures and methods of producing and using same
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833974A (en) * 1996-04-17 1998-11-10 Teicher; Beverly A. Method of enhancing the effective life of oxygen-delivery agents
US20050129747A1 (en) * 2002-03-20 2005-06-16 Wolfgang Barnikol Use of one or more natural or modified oxygen carriers, devoid of plasma and cellular membrane constiuents, for externally treating open, in particular chronic wounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONOVER, C. D. ET AL.: "The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models", ARTIF. CELLS BLOOD SUBSTIT. IMMOBIL. BIOTENHNOL., vol. 27, no. 2, March 1999 (1999-03-01), pages 93 - 107, XP008169461 *
ZHAO J. ET AL.: "Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers", BIOMATERIALS, vol. 28, no. 7, March 2007 (2007-03-01), pages 1414 - 1422, XP005812898 *

Also Published As

Publication number Publication date
WO2012094679A2 (en) 2012-07-12
EP2661275A4 (en) 2014-07-23
EP2661275B1 (en) 2019-01-02
ES2718308T3 (en) 2019-07-01
EP2661275A2 (en) 2013-11-13
US20130177641A1 (en) 2013-07-11
DK2661275T3 (en) 2019-04-15
PT2661275T (en) 2019-04-24
US20140255477A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
WO2012094679A3 (en) Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
Huang et al. Enzyme core spherical nucleic acid that enables enhanced cuproptosis and antitumor immune response through alleviating tumor hypoxia
Koonce et al. Combination of gold nanoparticle-conjugated tumor necrosis factor-α and radiation therapy results in a synergistic antitumor response in murine carcinoma models
Zhao et al. Nanomessenger-mediated signaling cascade for antitumor immunotherapy
Yuan et al. On-demand manipulation of tumorigenic microenvironments by nano-modulator for synergistic tumor therapy
MX348817B (en) Methods for treating cancer and non-neoplastic conditions.
Sang et al. Remodeling macrophages by an iron nanotrap for tumor growth suppression
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
Tian et al. An intelligent cupreous nanoplatform with self-supplied H2O2 and Cu2+/Cu+ conversion to boost cuproptosis and chemodynamic combined therapy
JO2932B1 (en) Pegylated insulin lispro compounds
HK1211832A1 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
RU2017126610A (en) THERAPEUTIC COMPOSITIONS AND METHODS AGAINST MALIGNANT TUMORS WITH RNC MOLECULES AIMED AGAINST HSP47
WO2008091375A3 (en) Attenuated salmonella as a delivery system for sirna-based tumor therapy
UA104634C2 (en) PEGYLOVAN L-ASPARAGINASE $PEGYLATED L-ASPARAGINASE
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
MX336710B (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases.
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
WO2007100675A3 (en) Collagenase for treating cellulite
WO2009128918A8 (en) Combination therapy using a soluble hyaluronidase and a bisphosphonate
SE0402025D0 (en) Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
WO2009135165A3 (en) Small humanin-like peptides
EP2061456A4 (en) Compositions and methods for inhibiting cytochrome p450
Andón et al. Innate and adaptive responses of intratumoral immunotherapy with endosomal toll-like receptor agonists
MX2020002568A (en) Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue.
Lin et al. Janus silica nanoparticle-based tumor microenvironment modulator for restoring tumor sensitivity to programmed cell death ligand 1 immune checkpoint blockade therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12732165

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13508271

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012732165

Country of ref document: EP